<![CDATA[Integrating MajesTEC-9 Data Into Treatment Decisions for Relapsed/Refractory Multiple Myeloma]]>

Summary

Medical professionals discuss how MajesTEC-9 clinical trial data may influence treatment decisions for relapsed/refractory multiple myeloma patients with early relapse following frontline therapy. The article appears to be educational commentary on recently presented trial data rather than a news announcement of new results.